Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160138022
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: December 1, 2015
    Publication date: May 19, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20160101128
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: October 9, 2015
    Publication date: April 14, 2016
    Inventors: Daqing Wang, Wayne Jiang, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9260719
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 16, 2016
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 9243050
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: January 26, 2016
    Assignee: Idera Pharamaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Putta, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9206430
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: December 8, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9096858
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 4, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
    Patent number: 8987221
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 24, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Compositions for Inhibiting Gene Expression and Uses Thereof
    Publication number: 20150044196
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Application
    Filed: September 24, 2014
    Publication date: February 12, 2015
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Tao Lan, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon
  • Stabilized immunomodulatory oligonucleotides
    Patent number: 8946175
    Abstract: The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5?- or 3?-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5?-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3?-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: February 3, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Lakshmi Bhagat, Rajendra K. Pandey, Dong Yu, Sudhir Agrawal
  • Compositions for inhibiting gene expression and uses thereof
    Patent number: 8877722
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: November 4, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon, Tao Lan
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8
    Publication number: 20140308300
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 16, 2014
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Putta, Sudhir Agrawal
  • Toll like receptor modulators
    Patent number: 8853375
    Abstract: The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Lakshmi Bhagat, Mallikarjuna Putta, Daqing Wang, Sudhir Agrawal
  • Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
    Patent number: 8853177
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20140193396
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 8759310
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 24, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 8716253
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: May 6, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20140004100
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: May 30, 2013
    Publication date: January 2, 2014
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20130267583
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: December 31, 2012
    Publication date: October 10, 2013
    Applicant: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8
    Publication number: 20130202584
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: January 19, 2012
    Publication date: August 8, 2013
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • Agonists of toll-like receptor 3 and methods of their use
    Patent number: 8492358
    Abstract: TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: July 23, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Tao Lan, Victoria Jane Philbin, Sudhir Agrawal